Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.

Leitinger, E J; Wright, R M; Nelson, N; Anderson, M A; Juneja, S

Leitinger, E J; Wright, R M; Nelson, N; Anderson, M A; Juneja, S.

Affiliation

Leitinger EJ; Department of Diagnostic Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Vic, Australia; Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Vic, Australia. Electronic address: Leitingerej@gmail.com.
Wright RM; Department of Diagnostic Haematology, The Royal Children's Hospital, Melbourne, Vic, Australia.
Nelson N; Department of Diagnostic Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Vic, Australia.
Anderson MA; Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Vic, Australia; Cancer and Haematology Division, Walter and Eliza Hall Institute, Parkville, Vic, Australia.
Juneja S; Department of Diagnostic Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Vic, Australia; Department of Medicine, The University of Melbourne, Parkville, Vic, Australia.

Pathology ; 53(7): 926-929, 2021 Dec.

Article in En | MEDLINE | ID: mdl-33947523

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperidines / Sulfonamides / Adenine / Antineoplastic Combined Chemotherapy Protocols / Bridged Bicyclo Compounds, Heterocyclic / Lymphoma, Mantle-Cell / Antineoplastic Agents Type of study: Diagnostic_studies Limits: Humans / Male / Middle aged Language: En Journal: Pathology Year: 2021 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google